Greg Abel Sells Berkshire Hathaway Stocks Managed by Former Investment Manager Todd Combs 
Elon Musk's Terafab Foundry Courts Top Chipmaking Giants for AI Self-Sufficiency Push 
CATL Stock Hits Record High After Q1 2025 Earnings Surge 
OpenAI's $20 Billion Cerebras Deal Signals Massive AI Infrastructure Push 
Uber Bets Big on Autonomous Vehicles with $10 Billion Commitment 
Hermès Q1 2026 Sales Miss Expectations Amid Iran War and China Slowdown 
KKR's $820M Investment Fuels Samsung SDS AI Expansion, Sending Group Shares Soaring 
Netflix Q2 Profit Warning Sends Shares Tumbling as Reed Hastings Exits 
Tesla's Terafab: AI Chip Factory Eyes Taiwan's Semiconductor Talent 
NiSource Signs Long-Term Energy Deals with Alphabet and Amazon to Power Indiana Data Centers 
How Technology Is Reshaping Modern Business: From Operations to Customer Experience 
TSMC Posts Record Q1 Profit Fueled by AI Chip Demand 
Elliott Investment Takes ~3% Stake in Daikin, Pushes for Buybacks and Strategic Overhaul 
Samsung Races to Deliver Next-Gen HBM4E Memory Samples to Nvidia 
Apple Wins ITC Ruling, Keeping Blood-Oxygen Feature on Apple Watch 
Federal Agencies Secretly Test Anthropic's AI Despite Trump Administration Ban 
Japan Opens Arms Export Floodgates: New Policy Draws Global Defense Interest 
LOS ANGELES, May 30, 2017 -- Lundin Law PC, a shareholder rights firm, announces the filing of a class action lawsuit against Neurotrope, Inc. (“Neurotrope” or the “Company”) (Nasdaq:NTRP) concerning possible violations of federal securities laws between January 7, 2016 and April 28, 2017, inclusive (the “Class Period”). Investors who purchased or otherwise acquired shares during the Class Period should contact the firm prior to the July 17, 2017 lead plaintiff motion deadline.
To participate in this class action lawsuit, click here.
You can also call Brian Lundin, Esq., of Lundin Law PC, at 888-713-1033, or you can e-mail him at [email protected].
No class has been certified in the above action yet. Until a class is certified, you are not considered represented by an attorney. You may also choose to do nothing and be an absent class member.
According to the Complaint, throughout the Class Period, Neurotrope issued materially false and misleading statements and/or failed to disclose material information concerning the efficacy of its lead product candidate, Bryostatin-1. On May 1, 2017, Neurotrope issued a press release announcing “positive top-line results” of the pivotal Phase 2b trials of Bryostatin-1, noting “improvement in patients with moderate to severe Alzheimer’s disease.” The underlying trial data contradicted these representations, as the top-line data relating to the 20-microgram dose of Bryostatin-1 failed to produce results that were statistically significant. Also, Neurotrope failed to disclose statements regarding the efficacy of the 40-microgram dose with regard to its primary and secondary endpoints. When this information was released, the Company’s shares fell in value, which harmed investors according to the Complaint.
Lundin Law PC was established by Brian Lundin, a securities litigator based in Los Angeles dedicated to upholding shareholders’ rights.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.
Contact: Lundin Law PC Brian Lundin, Esq. Telephone: 888-713-1033 Facsimile: 888-713-1125 [email protected] http://lundinlawpc.com/
